Scientific article
Open access

Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study

Published inAlzheimer's research & therapy, vol. 15, no. 1, 189
Publication date2023-11-02
First online date2023-11-02

Background: The mismatch between the limited availability versus the high demand of participants who are in the pre-dementia phase of Alzheimer's disease (AD) is a bottleneck for clinical studies in AD. Nevertheless, potential enrollment barriers in the pre-dementia population are relatively under-reported. In a large European longitudinal biomarker study (the AMYPAD-PNHS), we investigated main enrollment barriers in individuals with no or mild symptoms recruited from research and clinical parent cohorts (PCs) of ongoing observational studies.

Methods: Logistic regression was used to predict study refusal based on sex, age, education, global cognition (MMSE), family history of dementia, and number of prior study visits. Study refusal rates and categorized enrollment barriers were compared between PCs using chi-squared tests.

Results: 535/1856 (28.8%) of the participants recruited from ongoing studies declined participation in the AMYPAD-PNHS. Only for participants recruited from clinical PCs (n = 243), a higher MMSE-score (β =  - 0.22, OR = 0.80, p < .05), more prior study visits (β =  - 0.93, OR = 0.40, p < .001), and positive family history of dementia (β = 2.08, OR = 8.02, p < .01) resulted in lower odds on study refusal. General study burden was the main enrollment barrier (36.1%), followed by amyloid-PET related burden (PCresearch = 27.4%, PCclinical = 9.0%, X2 = 10.56, p = .001), and loss of research interest (PCclinical = 46.3%, PCresearch = 16.5%, X2 = 32.34, p < .001).

Conclusions: The enrollment rate for the AMYPAD-PNHS was relatively high, suggesting an advantage of recruitment via ongoing studies. In this observational cohort, study burden reduction and tailored strategies may potentially improve participant enrollment into trial readiness cohorts such as for phase-3 early anti-amyloid intervention trials. The AMYPAD-PNHS (EudraCT: 2018-002277-22) was approved by the ethical review board of the VU Medical Center (VUmc) as the Sponsor site and in every affiliated site.

  • Alzheimer’s disease
  • Amyloid PET
  • Clinical trial
  • Enrollment barriers
  • Preclinical
  • Recruitment
  • Humans
  • Alzheimer Disease / diagnostic imaging
  • Alzheimer Disease / epidemiology
  • Amyloid
  • Amyloid beta-Peptides
  • Amyloidogenic Proteins
  • Cognition
  • Cognitive Dysfunction
  • Longitudinal Studies
  • Positron-Emission Tomography
  • Male
  • Female
Citation (ISO format)
BADER, Ilse et al. Recruitment of pre-dementia participants : main enrollment barriers in a longitudinal amyloid-PET study. In: Alzheimer’s research & therapy, 2023, vol. 15, n° 1, p. 189. doi: 10.1186/s13195-023-01332-4
Main files (1)
Article (Published version)
Secondary files (1)
ISSN of the journal1758-9193

Technical informations

Creation03/26/2024 1:25:35 PM
First validation05/22/2024 2:25:38 PM
Update time05/22/2024 2:25:38 PM
Status update05/22/2024 2:25:38 PM
Last indexation05/22/2024 2:25:58 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack